Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The ...
Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...
13hon MSN
Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...
Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback